Bristol Myers Squibb (BMY) Asset Writedowns and Impairment (2010 - 2026)

Bristol Myers Squibb (BMY) has reported Asset Writedowns and Impairment for 17 consecutive years, with $422.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Asset Writedowns and Impairment rose 34.82% year-over-year to $422.0 million in Q2 2026; TTM through Jun 2026 was $1.6 billion, a 33.03% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, down 62.94% from the prior year.
• Asset Writedowns and Impairment was $422.0 million for Q2 2026 at Bristol Myers Squibb, up from $412.0 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $2.0 billion in Q4 2024 and troughed at $1.0 million in Q1 2024.
• A 5-year average of $296.1 million and a median of $100.0 million in 2022 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment slumped 95.0% in 2024 and surged 8140.0% in 2026, its largest moves.
• Over 5 years, Asset Writedowns and Impairment stood at $35.0 million in 2022, then decreased by 17.14% to $29.0 million in 2023, then surged by 6634.48% to $2.0 billion in 2024, then tumbled by 70.1% to $584.0 million in 2025, then decreased by 27.74% to $422.0 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $422.0 million (Q2 2026), $412.0 million (Q1 2026), and $584.0 million (Q4 2025), per Business Quant data.